Table 1.

Univariate analysis of the prognostic factors affecting survival

Factor	Number	P (log-rank test)
Age
<65/≥65	8/21	0.128
Location
Cervical/thoracic/lumbar/sacral	5/11/12/1	0.306
Junctional/mobile spine/semirigid/rigid	8/13/8/0	0.464
Karnofsky performance status
100–80/70–50/40–10	3/17/9	0.071
100–80/70–60/50–10	1/14/14	0.364
Visceral metastases
Present/not present	7/22	0.016*
Number of vertebral metastases
1/2/≥3	9/1/19	0.505
Number of extraspinal metastases
0/1–2/≥3	19/2/8	0.920
Preoperative Frankel score
A–C (not ambulatory)/D–E (ambulatory)	19/10	0.713
Revised Tokuhashi scores
0–8/9–11/12–15	7/16/6	0.048*
Tomita scores
7–10/2–6	6/23	0.084*
Crnalic prostate scores
0–1/2–4/5–6	7/20/2	0.133
PSA
<100/≥100	13/16	0.843
Hormone status 1
Hormone-naïve/hormone-refractory	20/9	0.024*
Hormone status 2
Hormone-naïve 1/hormone-naïve 2/hormone-refractory	16/4/9	0.109
Bisphosphonate treatment
Yes/no	16/13	0.011*
Urinary and bowel continence
Yes/no	24/5	0.900
History of PCa
Yes/no	15/14	0.386

Hormone-naïve 1 means patients with spinal metastases as the initial manifestation of PCa. Hormone-naïve 2 means patients who previously underwent prostatectomy and did not receive hormonal therapy

*P value less than 0.1 for the multivariate analysis